<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200989</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-19-7380</org_study_id>
    <nct_id>NCT04200989</nct_id>
  </id_info>
  <brief_title>Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy</brief_title>
  <official_title>Intra-lymphatic Immunotherapy for the Management of Peanut Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance
      to peanut in peanut allergic people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subject undergo a baseline blinded oral peanut challenge. Then the peanut ILIT as
      described above. Pretreatment with antihistamines, leukotriene modifier and albuterol before
      each treatment.

      Following the three ILIT peanut injections a repeat blinded oral peanut challenge is
      performed.

      Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the
      mechanism(s) of the induction of tolerance to peanut.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects receive the study intervention: Peanut ILIT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peanut tolerance</measure>
    <time_frame>4 months</time_frame>
    <description>Increase in amount (mg - grams) of peanut ingested without reaction from baseline to one month post ILIT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Food Allergy Peanut</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peanut ILIT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peanut allergen</intervention_name>
    <description>Intralymphatic immunotherapy injections.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        History of peanut allergy Positive prick skin tests or invitro IgE to peanut Positive
        blinded oral peanut challenge.

        -

        Exclusion Criteria:

        History of

          -  life threatening anaphylaxis to peanut Uncontrolled asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon A Ronald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer A Namazy, MD</last_name>
    <phone>(619) 245-2790</phone>
    <email>Namazy.Jennifer@scrippshealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald A Simon, MD</last_name>
    <phone>858-764-9010</phone>
    <email>simon.sonald@scrippshealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>373910049971004 Simon, MD</last_name>
      <phone>858-764-9010</phone>
      <email>rsimon@scrippsclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer A Namazy, MD</last_name>
      <phone>6192452790</phone>
      <email>Namazy.Jennifer@scrippshealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Grönlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kündig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.</citation>
    <PMID>22464647</PMID>
  </reference>
  <reference>
    <citation>Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.</citation>
    <PMID>23374268</PMID>
  </reference>
  <reference>
    <citation>Lee SP, Choi SJ, Joe E, Lee SM, Lee MW, Shim JW, Kim YJ, Kyung SY, Park JW, Jeong SH, Jung JH. A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies. Allergy Asthma Immunol Res. 2017 May;9(3):272-277. doi: 10.4168/aair.2017.9.3.272.</citation>
    <PMID>28293934</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>Ronald A Simon</investigator_full_name>
    <investigator_title>Emeritus Head, Division of Asthma, Allergy and Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

